BCM
ESPR

Bridgeway Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Bridgeway Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-37,000
Closed -$248K – 1398
2022
Q3 		$248K Sell
37,000
-70,000
-65% -$481K 0.01% 1092
2022
Q2 		$681K Hold
107,000
– – 0.02% 808
2022
Q1 		$496K Buy
+107,000
New +$459K 0.01% 939
2015
Q2 		– Sell
-15,200
Closed -$1.41M – 1503
2015
Q1 		$1.41M Sell
15,200
-17,000
-53% -$1.1M 0.03% 657
2014
Q4 		$1.3M Sell
32,200
-3,300
-9% -$101K 0.03% 686
2014
Q3 		$868K Buy
35,500
+9,800
+38% +$156K 0.02% 806
2014
Q2 		$407K Buy
25,700
+700
+3% +$10.1K 0.01% 1178
2014
Q1 		$378K Buy
+25,000
New +$388K 0.01% 1191

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Bridgeway Capital Management's ESPR Position: Q4 2022 in Review

Bridgeway Capital Management sold out of Esperion Therapeutics (ESPR) in Q4 2022, closing a stake of 37,000 shares — an estimated $248K sold.

Bridgeway Capital Management first reported a position in ESPR in Q1 2014 and held it in 8 quarters. The position peaked at $1.41M in Q1 2015. 165 funds tracked by Wall St. Rank hold ESPR as of Q4 2022.

  • Bridgeway Capital Management reported no remaining Esperion Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Bridgeway Capital Management sold 37,000 Esperion Therapeutics shares in Q4 2022, an estimated $248K.
  • Bridgeway Capital Management first reported a position in Esperion Therapeutics in Q1 2014 and held it in 8 quarters.
  • Bridgeway Capital Management's Esperion Therapeutics position peaked at $1.41M in Q1 2015.
  • 165 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2022.

Based on Bridgeway Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.